ACIP voted to recommend against anyone — adult, child and pregnant person — receiving a seasonal flu vaccine with the mercury ...

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

The first bacteria our bodies meet – in the hours after we're born – could protect us from dangerous infections, UK scientists say. They have shown, for the first time, that good bacteria seem to ...

The primers used for group determination were generated against the N and P regions of the RSV genome, according to the methods by Stockton et al (1998). Ten microliters of each RT-PCR product was ...

In fact, while more than 2 million children under age 5 make an RSV-related outpatient visit each year with some 58,000 to 80,000 of them ending up in the hospital, far more older adults infected ...

The World Health Organization (WHO) today published recommendations for two immunization products to protect infants against respiratory syncytial virus (RSV). Published in the Weekly Epidemiological ...

Of 695 RSV-infected infants, 545 full-length RSV genome sequences were analysed, with 260 (48%) from nirsevimab-treated breakthrough infections and 285 (52%) from untreated infants. RSV-A was the ...

RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is generally safe and well tolerated with no serious adverse events reported in ...

Sanofi executives also pointed to the company’s new RSV vaccine for newborns, Beyfortus, approved by the FDA in mid-2023. Last year, the vaccine brought in €1.7 billion ($1.77 billion) in 2024.